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We are pleased that Williams and coworkers [1] confirmed our
random effects analysis [2], which relied on publicly available
data. This analysis pooled the results from patients with Acute
Physiology and Chronic Health Evaluation (APACHE) II scores
of 25 or greater from the PROWESS (Recombinant Human
Activated Protein C Worldwide Evaluation of Severe Sepsis)
[3] and ADDRESS (Administration of Drotrecogin Alfa
[Activated] in Early Stage Severe Sepsis) [4] trials. As we
discussed previously [5], this analysis demonstrates a
surprising degree of statistical heterogeneity, which remains
despite minimal methodologic differences between the two
trials and further minimization of clinical heterogeneity by
selecting a more uniform subgroup of patients with severe
sepsis and a high risk for death. This heterogeneity is
illustrated in Figure 1 presented by Williams and coworkers
[1], in which I2 (the percentage of total variation in results
across studies that is due to heterogeneity rather than
chance [6]), is more than 80% for each of the methods
presented. Given this degree of unexplained heterogeneity,
the use of a fixed effects model, as suggested by Williams
and coworkers [1], would be highly unconventional [7].
We also support the pooling of individual patient data from
these trials to generate hypotheses regarding appropriate
patient selection for drotrecogin alfa (activated) that could be
tested in subsequent trials [5]. Furthermore, we encourage
public release of these data for the purposes of a meta-
analysis of individual patient data to be undertaken by an
independent group, using appropriate statistical methods that
incorporate random effects, and that is subject to peer review.
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